Igc Pharma Inc (IGC) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $255.9K

IGC ranks #6957 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IGC is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

37 institutions disclose a position in IGC, but none treat it as a major bet — even AdvisorShares Investments LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

IGC reported a net loss of $8.8M over the trailing twelve months.

• Not yet profitable — net loss of $8.8M over the trailing twelve months
• Revenue declined 17.0% year over year
• Net income declined year over year, from -$6.3M to -$8.8M
• Operating cash flow was negative, using $4.8M in cash
• Current ratio of 1.28x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.38x equity — within a conventional range